Reg FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2022 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 52 Sunrise Park Road , New Hampton , NY 10958 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: ( 845 ) 326-5600 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $.06-2/3 per share. BCPC NASDAQ Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company        ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.          ☐ Item 7.01 Regulation FD Disclosure. On August 30, 2022, Balchem Corporation (the “Company”) issued a press release announcing that its wholly-owned subsidiary Albion Laboratories, Inc. (“Albion”) entered into a Stock Purchase Agreement, and closed on such transaction, with Cardinal Associates, Inc. (“ Cardinal”), a corporation organized under the laws of the State of Washington, pursuant to which Albion acquired Cardinal and its Bergstrom Nutrition business. Bergstrom Nutrition is a global leader in the manufacture of MSM (methylsulfonylmethane), a nutritional ingredient with benefits for joint health, sports nutrition, skin and beauty, healthy aging, and pet health. A copy of the press release is furnished with this report as Exhibit 99.1 and incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d)  Exhibits Exhibit Number Description 99.1 Press release dated August 30, 2022 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   BALCHEM CORPORATION   (Registrant)       By: /s/ Hatsuki Miyata     Hatsuki Miyata   General Counsel and Secretary     Date: August 30, 2022